GRIP Molecular Technologies, Inc.
GRIP Molecular is a Minnesota-based biotech company dedicated to developing next-generation medical diagnostics that enable lab-quality results in minutes for homes and clinics. Their innovative nucleic acid amplification process significantly increases diagnostic accuracy, sensitivity, and specificity, making rapid testing easy, sample-agnostic, and cost-effective. The company's mission is to provide lab-grade diagnostic results at the point-of-need, transforming healthcare with technology that is accessible, reliable, and fast.
Industries
Nr. of Employees
small (1-50)
GRIP Molecular Technologies, Inc.
University Enterprise Labs, 1000 Westgate Drive Suite 122, Saint Paul, MN 55114
Patents
Products
Point-of-need nucleic acid-enhanced diagnostic platform (in development)
A diagnostic platform that combines non-thermal nucleic acid amplification with enhanced lateral flow and a solid-state biosensor to deliver laboratory-grade sensitivity and specificity at the point-of-need, with wireless smartphone readout.
Point-of-need nucleic acid-enhanced diagnostic platform (in development)
A diagnostic platform that combines non-thermal nucleic acid amplification with enhanced lateral flow and a solid-state biosensor to deliver laboratory-grade sensitivity and specificity at the point-of-need, with wireless smartphone readout.
Services
Partnerships and collaboration for development, testing, and commercialization of diagnostic technologies, including grant-supported projects.
Partnerships and collaboration for development, testing, and commercialization of diagnostic technologies, including grant-supported projects.
Expertise Areas
- Point-of-care diagnostics
- Molecular diagnostics
- Biosensor development
- Non-thermal nucleic acid amplification
Key Technologies
- Non-thermal nucleic acid amplification (NTA)
- Lateral flow assay enhancement
- Graphene-based solid-state biosensors
- Dielectrophoresis-enhanced target capture
News & Updates
GRIP Molecular announces the formation of a Board of Directors with Edward Ludwig accepting the role of Chairman of the Board. The company is developing a proprietary electronic biosensor for rapid, accurate detection of disease and health biomarkers in minutes using a standard cell phone.
Seven University of Minnesota startup companies, including GRIP Molecular, received Launch Minnesota Innovation Grants to support promising, innovative, and scalable technology businesses in Minnesota.
GRIP Molecular received both the 'People’s Choice' and 'Judge’s Choice' awards during the MedCity News – INVEST Pitch Perfect contest, highlighting its innovative approach in healthcare diagnostics.
Edward Ludwig, Board Chairman of GRIP Molecular, received the 2021 AdvaMed Lifetime Achievement Award for his impactful career in the medical technology industry.
Edward Ludwig, former CEO of Becton Dickinson, was honored with the 2021 AdvaMed Lifetime Achievement Award for his contributions to the medical technology industry.
GRIP Molecular was recognized as a winner in the INVEST Pitch Perfect 2021 contest, receiving both the 'People’s Choice' and 'Judge’s Choice' awards.
GRIP Molecular announces the formation of a Board of Directors with Edward Ludwig accepting the role of Chairman of the Board. The company is developing a proprietary electronic biosensor for rapid, accurate detection of disease and health biomarkers in minutes using a standard cell phone.
Seven University of Minnesota startup companies, including GRIP Molecular, received Launch Minnesota Innovation Grants to support promising, innovative, and scalable technology businesses in Minnesota.
GRIP Molecular received both the 'People’s Choice' and 'Judge’s Choice' awards during the MedCity News – INVEST Pitch Perfect contest, highlighting its innovative approach in healthcare diagnostics.
Edward Ludwig, Board Chairman of GRIP Molecular, received the 2021 AdvaMed Lifetime Achievement Award for his impactful career in the medical technology industry.
Edward Ludwig, former CEO of Becton Dickinson, was honored with the 2021 AdvaMed Lifetime Achievement Award for his contributions to the medical technology industry.
GRIP Molecular was recognized as a winner in the INVEST Pitch Perfect 2021 contest, receiving both the 'People’s Choice' and 'Judge’s Choice' awards.